Prostate cancer imaging drug showdown ends early
NCT ID NCT06516510
First seen Sep 30, 2025 · Last updated May 02, 2026 · Updated 29 times
Summary
This early-stage study aimed to compare two radioactive drugs (lutetium rhPSMA-10.1 and Pluvicto) in 17 men with advanced prostate cancer that cannot be cured. The goal was to see which drug delivers more radiation to tumors while sparing the kidneys. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Biogenix Molecular LLC
Miami, Florida, 33165, United States
-
Centro Integral Oncologico Clara Campal
Madrid, Madrid, 28050, Spain
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, Navarre, 31008, Spain
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Radboud UMC
Nijmegen, Gelderland, 6525GA, Netherlands
Conditions
Explore the condition pages connected to this study.